Atlas Trials

Akeso

153 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Akeso

RecordFirmDate
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma (NCT05008783)Akeso2021-09-17
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (NCT04982237)Akeso2021-08-27
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (NCT04982276)Akeso2021-08-23
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT04974398)Akeso2021-08-16
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia (NCT04980885)Akeso2021-08-13
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer (NCT04999605)Akeso2021-06-24
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome (NCT04900350)Akeso2021-06-18
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis (NCT05467995)Akeso2021-06-02
A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC (NCT04900363)Akeso2021-05-21
Study of AK112 in the Treatment of Advanced Gynecological Tumors (NCT04870177)Akeso2021-04-09
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC (NCT05116007)Akeso2021-03-29
A Phase 1 Dose Escalation and Expansion Study of AK117 (NCT04728334)Akeso2021-03-23
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (NCT04736810)Akeso2021-02-25
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (NCT04736823)Akeso2021-02-01
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (NCT04728321)Akeso2021-01-27
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors (NCT04572152)Akeso2020-12-07
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT04647344)Akeso2020-11-24
A Trial of AK104 Plus Anlotinib in NSCLC (NCT04646330)Akeso2020-11-18
A Study of AK112 for Advanced Solid Tumors (NCT04597541)Akeso2020-10-21
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer (NCT04380805)Akeso2020-07-15
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (NCT04444167)Akeso2020-07-07
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors (NCT04547205)Akeso2020-06-06
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis (NCT05504317)Akeso2020-05-28
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma (NCT04444141)Akeso2020-05-15
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia (NCT04358432)Akeso2020-05-13
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma (NCT04220307)Akeso2020-04-26
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors (NCT04172454)Akeso2019-12-20
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (NCT04173637)Akeso2019-12-19
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT04173793)Akeso2019-11-18
A Long-term Study of AK102 in Patients With Hypercholesterolemia (NCT04173403)Akeso2019-11-04
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors (NCT04172506)Akeso2019-09-10
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH (NCT03933293)Akeso2019-05-13
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma (NCT03866967)Akeso2019-03-27
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma (NCT03852251)Akeso2019-01-18
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer (NCT03866980)Akeso2018-11-27
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) (NCT04172571)Akeso2018-11-22
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma (NCT03722147)Akeso2018-08-13
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects (NCT04169386)Akeso2018-05-23
A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (NCT04172233)Akeso2018-01-09
← Previous

Track Akeso automatically

Every clearance here is in the API, with alerts when new ones post.